StockData
Corvus Pharmaceuticals, Inc. logo

Corvus Pharmaceuticals, Inc. (CRVS) stock

CRVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$10.17−0.43 (-4.06%)

Close on Nov 17, 2026Market cap $855.51MP/E –Yield –

Earnings

Corvus Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 11, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.22
-$0.12 a year earlier
Latest guidance
Lowered
Nov 12, 2024 · 2 items

Quarterly results

Revenue and earnings per share from each of Corvus Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 11, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026after the close––-$0.22Release
Q2 FY2026ended Jun 30, 2026Aug 6, 2026during market hours–––Release
Q1 FY2026ended Mar 31, 2026May 7, 2026during market hours––-$0.15Release
Q4 FY2025ended Dec 31, 2025Mar 12, 2026during market hours––-$0.15Release
Q3 FY2025ended Sep 30, 2025Nov 4, 2025during market hours––-$0.12Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025during market hours––-$0.10Release
Q1 FY2025ended Mar 31, 2025May 8, 2025during market hours––-$0.13Release
Q4 FY2024ended Dec 31, 2024Mar 25, 2025during market hours––-$0.18Release
Q3 FY2024ended Sep 30, 2024Nov 12, 2024during market hours–––Release
Q2 FY2024ended Jun 30, 2024Aug 6, 2024during market hours––-$0.07Release
Q1 FY2024ended Mar 31, 2024May 6, 2024during market hours––-$0.12Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period Corvus Pharmaceuticals guided for has been reported

Guidance history

Every forecast Corvus Pharmaceuticals put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 12, 2024projected cash balanceQ4 FY2024$38.00M – $39.00MNew
Nov 12, 2024net cash used in operating activitiesFY2024$25.00M – $26.00MLowered
Aug 6, 2024net cash used in operating activitiesFY2024$24.00M – $27.00MLowered
Aug 6, 2024projected cash balanceFY2024$31.00M – $34.00MRaised
May 6, 2024net cash used in operating activitiesFY2024$24.00M – $27.00MNew
May 6, 2024projected cash balanceFY2024$31.00M – $34.00MRaised
Nov 7, 2023net cash used in operating activitiesFY2023$22.00M – $23.00MLowered
Nov 7, 2023projected cash balanceFY2023$27.00M – $28.00MRaised
Aug 8, 2023net cash used in operating activitiesFY2023$20.00M – $22.00MLowered
Aug 8, 2023projected cash balanceFY2023$28.00M – $30.00MRaised
May 8, 2023net cash used in operating activitiesFY2023$19.00M – $22.00MLowered
May 8, 2023projected cash balanceFY2023$20.00M – $23.00MRaised
Mar 28, 2023net cash used in operating activitiesFY2023$19.00M – $22.00MNew
Mar 28, 2023projected cash balanceFY2023$20.00M – $23.00MRaised
Nov 3, 2022net cash used in operating activitiesFY2022$27.00M – $29.00MLowered
Nov 3, 2022projected cash balanceFY2022$40.50M – $42.50MRaised
Aug 8, 2022net cash used in operating activitiesFY2022$27.00M – $29.00MLowered
Aug 8, 2022projected cash balanceFY2022$40.50M – $42.50MRaised
Mar 10, 2022net cash used in operating activitiesFY2022$34.00M – $36.00MNew
Nov 1, 2021net cash used in operating activitiesFY2021$36.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Corvus Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Update
  4. Results
  5. Results
  6. Update
  7. Results
  8. Results
  9. Update
  10. Results
  11. Results
  12. Results
  13. Update
  14. Update
  15. Results

See a number that looks wrong?